TGA gets first BiTE in new approvals

By Megan Brodie 1 year ago | In Products, Regulatory
  • 1 year ago

30 June 2025 Amgen’s first-in-class bispecific T-cell engager (BiTE) therapy IMDELLTRA (tarlatamab) has been approved…

This is subscriber-only content. Please login to continue reading.

Recent News

Top Reads